Bahrain



Tuberculosis profile

Population 2010 (millions)


| Estimates of burden * 2010 | Number (thousands) | Rate (per 100 000 pop) |
|-------------------------------|---------------------|---------------------------|
| Mortality (excluding HIV) | 0.011 (0.01-0.012) | 0.9 (0.83-0.97) |
| Prevalence (incl HIV) | 0.32 (0.076-0.57) | 26 (6-45) |
| Incidence (incl HIV) | 0.29 (0.26-0.33) | 23 (20-26) |
| Incidence (HIV-positive) | 0.011 (<0.01-0.022) | 0.84 (0.27-1.7) |
| Case detection, all forms (%) | 85 (75–95) | |

| Case notifications 2010 | | | |
|-------------------------|-----|------------------------------|-----|
| New cases | | (%) Retreatment cases | (%) |
| Smear-positive | 90 | (37) Relapse | 0 |
| Smear-negative | 58 | (24) Treatment after failure | 0 |
| Smear unknown | 0 | (0) Treatment after default | 0 |
| Extrapulmonary | 98 | (40) Other | 0 |
| Other | 0 | (0) | |
| Total new | 246 | Total retreatment | 0 |
| Total < 15 years | 5 | | |

| Total new and relapse | 246 | (100% of total) |
|-----------------------|-----|-----------------|
| Total cases notified | 246 | |

| Drug regimens | |
|---|-----|
| Rifampicin used throughout treatment | Yes |
| % of patients treated with fixed-dose combinations (FDCs) | 0 |
| Pandiatric formulations procured | Voc |





| MDR-TB, Estimates among notified cases * | |
|--|---------------|
| % of new TB cases with MDR-TB | 0.0 (0.0-2.3) |
| % of retreatment TB cases with MDR-TB | |
| Estimated MDR-TB cases among new pulmonary TB cases notified in 2010 | |
| Estimated MDR-TB cases among retreated | |

| MDR-TB reported cases 2010 | New | Retreat- ment | Total |
|------------------------------------|------|------------------|-------|
| Cases tested for MDR-TB | 162 | 0 | 162 |
| % of notified tested for MDR-TB | 66 | | 66 |
| Confirmed cases of MDR-TB | 0 | 0 | 0 |
| MDR-TB patients started treatment | | | 0 |
| Laboratories | 2009 | 2010 | 2011 |
| Smear (per 100 000 population) | 1.5 | 1.4 | |
| Culture (per 5 million population) | 8.6 | 7.9 | |
| DST (per 5 million population) | 4.3 | 4.0 | |


Outside country


No


| * Pangos | roprosont uncortainty intonvals |
|----------|---------------------------------|

Second-line DST available


National Reference Laboratory







| TB/HIV 2010 | |
|--|-----|
| TB patients with known HIV status | 161 |
| % of TB patients with known HIV status | 65 |
| TB patients that are HIV-positive | 6 |
| % of tested TB patients that are HIV-positive | 4 |
| % HIV-positive TB patients started on CPT | 0 |
| % HIV-positive TB patients started on ART | 0 |
| HIV-positive people screened for TB | |
| HIV-positive people provided with IPT | |
| CPT (orange) and ART (green) for HIV-positive TB patients (blue) | |



| Financing | 2011 | 2012 |
|--|----------------|------|
| Total budget (US\$ millions) | | 0 |
| Available funding (US\$ millions) | 0 | 0 |
| % of budget funded | | |
| % available funding from domestic sources | | |
| % available funding from Global Fund | | |
| NTP Budget (blue) and available funding (green) (l | JS\$ millions) | |

